Literature DB >> 10997986

Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII.

D W Jones1, M J Gallimore, I J MacKie, S L Harris, M Winter.   

Abstract

Antibodies to factor XII (FXII) have previously been identified in some patients who were lupus anti-coagulant-positive. The relationship between these antibodies and FXII levels appeared to be variable. The aim of the present study was to confirm the presence of antibodies to FXII in patients with well characterized antiphospholipid syndrome (APS) and to establish their potential effect on levels of FXII. Forty-two patients with APS were studied; 21 patients were found to have either immunoglobulin (Ig)G or IgM antibodies to FXII by enzyme-linked immunosorbent assay (ELISA) using a highly purified preparation of FXII (> 99% pure). Levels of FXII were statistically significantly lower (P = 0.02) in patients with antibodies to FXII when compared with patients without antibodies to FXII (median = 91 micro/dl, s.d. = 39.1, median = 122 micro/dl, s.d. = 41.1 respectively). Four of the 21 patients with antibodies to FXII were found to have FXII levels below the laboratory normal range. Antibodies to FXII are present in significant numbers of patients with APS and may lead to acquired FXII deficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997986     DOI: 10.1046/j.1365-2141.2000.02251.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus.

Authors:  Maria Laura Bertolaccini; Kirti Mepani; Giovanni Sanna; Graham R V Hughes; Munther A Khamashta
Journal:  Ann Rheum Dis       Date:  2006-10-04       Impact factor: 19.103

2.  Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

Authors:  Alexey S Revenko; Dacao Gao; Jeff R Crosby; Gourab Bhattacharjee; Chenguang Zhao; Chris May; David Gailani; Brett P Monia; A Robert MacLeod
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

3.  Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis.

Authors:  Anastasia Lambrianides; Tabitha Turner-Stokes; Charis Pericleous; Jasmine Ehsanullah; Eva Papadimitraki; Katie Poulton; Yiannis Ioannou; Andrew Lawrie; Ian Mackie; Pojen Chen; David Latchman; David Isenberg; Anisur Rahman; Ian Giles
Journal:  Arthritis Rheum       Date:  2011-11

4.  Acquired factor XII deficiency in a woman with recurrent pregnancy loss: working on a differential diagnosis in a single case.

Authors:  Maristella D'Uva; Ida Strina; Antonio Mollo; Antonio Ranieri; G De Placido; P Di Micco
Journal:  J Transl Med       Date:  2005-12-02       Impact factor: 5.531

5.  Anti-Factor XII Autoantibodies in Patients with Recurrent Pregnancy Loss Recognize the Second Epidermal Growth Factor-Like Domain.

Authors:  Yoshihiro Sato; Toshitaka Sugi; Rie Sakai
Journal:  TH Open       Date:  2019-09-03

Review 6.  The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System.

Authors:  R Arreola-Diaz; A Majluf-Cruz; L E Sanchez-Torres; J Hernandez-Juarez
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

7.  Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus.

Authors:  Jennie Bäck; Christian Lood; Anders A Bengtsson; Kristina Nilsson Ekdahl; Bo Nilsson
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

8.  Genotyping analysis for the 46 C/T polymorphism of coagulation factor XII and the involvement of factor XII activity in patients with recurrent pregnancy loss.

Authors:  Eriko Asano; Takeshi Ebara; Chisato Yamada-Namikawa; Tamao Kitaori; Nobuhiro Suzumori; Kinue Katano; Yasuhiko Ozaki; Makoto Nakanishi; Mayumi Sugiura-Ogasawara
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.